ByTrending Posts
Is the U.S. Reopening the Door to Coverage…
23 January 2026 Executive Summary The expiration of enhanced Affordable Care Act (ACA) subsidies is continuing to drive…
Does the U.S. Exit from WHO Redefine Global…
23 January 2026 Executive Summary The United States has formally completed its withdrawal from the World Health Organization…
Does the U.S. Exit from WHO Redefine Global…
23 January 2026 Executive Summary The United States has formally completed its withdrawal from the World Health Organization…
Is Partnership-Led Innovation Replacing M&A in Oncology? BMS…
January 2026 Executive Summary Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Janux Therapeutics, a…
Is Partnership-Led Innovation Replacing M&A in Oncology? BMS…
22 January 2026 Executive Summary Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Janux Therapeutics,…
Can Global Partnerships Future-Proof Epidemic Preparedness? SK bioscience,…
23 January 2026 Executive Summary A global vaccine partnership has been established between SK bioscience, MSD (Merck &…
Is Strategic Out-Licensing the Fastest Path to Global…
23 January 2026 Executive Summary Restari has secured exclusive global out-licensing rights from AriBio for a next-generation PDE-5…
Is GSK Buying Its Way Past the Patent…
January 2026 Executive Summary GSK has agreed to acquire Rapt Therapeutics, a U.S.-based biotech focused on inflammatory and…
Is AI Poised to Replace the Traditional Drug…
23 January 2026 Executive Summary Nvidia CEO Jensen Huang has underscored the transformative potential of artificial intelligence in…
Trending Posts
Latest Stories
Will Johnson & Johnson’s 2025 Earnings Reinforce Confidence in Its Pharma-Led Growth Engine?
Late January 2026 | Full-Year 2025 Earnings Preview | Diversified Pharma Outlook Johnson & Johnson…
Can Pfizer’s 2025 Earnings Reignite Confidence in Its Post-COVID Portfolio and Late-Stage Pipeline?
Late January 2026 | Full-Year 2025 Earnings Preview | Big Pharma Strategy Reset Pfizer is…
Will Novartis’ January 2026 Earnings Validate the Strength of Its Focused Portfolio and Late-Stage Pipeline?
January 30, 2026 | Full-Year 2025 Earnings Preview | Innovative Medicines Outlook Novartis is scheduled…
Will Roche’s 2025 Earnings Reset the Narrative for 2026 Growth and Pipeline Confidence?
January 29, 2026 | Full-Year Earnings | Big Pharma Outlook Roche is set to publish…
Gallery
